Ramping Up Its COVID Response, EU Will Buy Up To 1.8B Doses Of Pfizer Vaccine

[Hamartia Antidote]

Ramping Up Its COVID Response, EU Will Buy Up To 1.8B Doses Of Pfizer Vaccine

The agreement provides a significant boost to the European Union's goal of getting 70% of adults vaccinated. Currently, around a quarter of the bloc's population is vaccinated.

www.npr.org

The European Union and Pfizer-BioNTech have signed a deal for up to 1.8 billion doses of the COVID-19 vaccine. The bloc's biggest contract to date would cover its entire population, marking a significant ramp up in its fight against the coronavirus.

EU Commission President Ursula von der Leyen announced the deal in a tweet, writing it is for a " for guaranteed 900 million doses (+900 million options)."

Von der Leyen says other contracts and vaccines are coming for the 27-member bloc with a population of around 450 million.

The enormous Pfizer-BioNTech contract for the two-dose shot would help cover future unknowns including whether a booster shot will be required and what will happen with circulating variants.

The agreement calls for vaccine production to happen within the EU. Delivery will likely extend into 2023.

Last month, the commission announced 250 million Pfizer-BioNTech doses would be delivered by June. The EU's executive arm approved use of the vaccine late last year after the European Medicines Agency, gave its authorization.

The EU is distributing vaccines from a half-dozen companies. Other vaccines remain in development. Some 160 million doses have been administered, with a quarter of the population already vaccinated.

But the virus is still spreading. France, Italy and Spain are currently reporting the most COVID-19 cases. In its bid to contain transmission, the EU is aiming to get 70% of adults vaccinated.


The Pfizer-BioNTech deal underscores confidence in the vaccine. For its part, the Oxford-AstraZeneca vaccine has had halting rollout in the EU, with delivery delays and warnings about rare blood clots occurring in some recipients.

In the U.S., approximately 170 million Pfizer-BioNTech vaccines have been delivered, according to the Centers for Disease Control and Prevention, with nearly 140 million shots administered. Three vaccines are authorized for emergency use and nearly 60% of the adult population has gotten at least one shot.

The Pfizer-BioNTech vaccine was the first approved in the U.S. in December when federal officials granted emergency use authorization.

Now the U.S.-based Pfizer and its German partner BioNTech are requesting full approval in the U.S. for people 16 and older, a process that involves more rigorous oversight, including providing follow-up data six months after vaccinations.

The vaccine maker is also seeking emergency use authorization in the U.S. to include children 12 to 15 years old.

 

[vi-va]

It's Germany BioNtech to be specific. Pfizer is just manufacturer.

It's like China manufacturer iPhone, but China never claimed iPhone is Chinese phone.

While India manufacture Xiaomi, but Xiaomi is still Chinese phone.

 

[dbc]

It's Germany BioNtech to be specific. Pfizer is just manufacturer.

It's like China manufacturer iPhone, but China never claimed iPhone is Chinese phone.

While India manufacture Xiaomi, but Xiaomi is still Chinese phone.

The IP belongs to University of Pennsylvania, so its American.

Patent Sublicense Agreement ​

This Patent Sublicense Agreement (“Agreement”) is between CELLSCRIPT, LLC, a Wisconsin limited liability company having a place of business at 726 Post Road, Madison, WI 53713, USA (“Cellscript”) and ModernaTx, Inc., a Delaware corporation having a place of business at 320 Bent Street, Cambridge, MA 02141, USA (“Company”). This Agreement is effective as of June 26, 2017 (the “Effective Date”). Each of Company and Cellscript are referred to herein as a “Party” and collectively as the “Parties”.

BACKGROUND

WHEREAS, mRNA RiboTherapeutics, Inc. (“mRNA RiboTherapeutics”) has an exclusive license from the Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”) for certain intellectual property comprising patents, patent applications and technology relating to use of modified ribonucleic acid (RNA) technology which was developed by Drs. Drew Weissman and Katalin Kariko of Penn’s Perelman School of Medicine as described in [***], and certain other intellectual property comprising patents, patent applications and technology relating to the modified RNA technology, inter alia, for reprogramming of mammalian cells to induced pluripotent stem cells, as described in [***], pursuant to the Second Amended and Restated Patent License Agreement which became effective as of December 20, 2016 (the “Penn License Agreement”), under which Cellscript has a sublicense from mRNA RiboTherapeutics in certain fields of use pursuant to the Amended and Restated Patent Sublicense Agreement which became effective as of December 20, 2016 (the “Cellscript Sublicense Agreement”), under which Cellscript has the right to further sublicense all or any part of the rights granted to Cellscript to other parties; and

EX-10.8

www.sec.gov

 

[UKBengali]

EU is supporting Pfizer partly because it was developed by BionTech.

It is a German/USA product.

 

[vi-va]

The IP belongs to University of Pennsylvania, so its American.

Patent Sublicense Agreement ​

This Patent Sublicense Agreement (“Agreement”) is between CELLSCRIPT, LLC, a Wisconsin limited liability company having a place of business at 726 Post Road, Madison, WI 53713, USA (“Cellscript”) and ModernaTx, Inc., a Delaware corporation having a place of business at 320 Bent Street, Cambridge, MA 02141, USA (“Company”). This Agreement is effective as of June 26, 2017 (the “Effective Date”). Each of Company and Cellscript are referred to herein as a “Party” and collectively as the “Parties”.

BACKGROUND

WHEREAS, mRNA RiboTherapeutics, Inc. (“mRNA RiboTherapeutics”) has an exclusive license from the Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”) for certain intellectual property comprising patents, patent applications and technology relating to use of modified ribonucleic acid (RNA) technology which was developed by Drs. Drew Weissman and Katalin Kariko of Penn’s Perelman School of Medicine as described in [***], and certain other intellectual property comprising patents, patent applications and technology relating to the modified RNA technology, inter alia, for reprogramming of mammalian cells to induced pluripotent stem cells, as described in [***], pursuant to the Second Amended and Restated Patent License Agreement which became effective as of December 20, 2016 (the “Penn License Agreement”), under which Cellscript has a sublicense from mRNA RiboTherapeutics in certain fields of use pursuant to the Amended and Restated Patent Sublicense Agreement which became effective as of December 20, 2016 (the “Cellscript Sublicense Agreement”), under which Cellscript has the right to further sublicense all or any part of the rights granted to Cellscript to other parties; and

EX-10.8

www.sec.gov

BioNTech and Pfizer’s BNT162 Vaccine Patent Landscape

BioNTech and Pfizer’s BNT162 Vaccine Patent Landscape - Public Citizen

Safe and effective vaccines are key to combating the Covid-19 pandemic; however, patents and other intellectual property claims directed at…

www.citizen.org

 

[dbc]

BioNTech and Pfizer’s BNT162 Vaccine Patent Landscape

BioNTech and Pfizer’s BNT162 Vaccine Patent Landscape - Public Citizen

Safe and effective vaccines are key to combating the Covid-19 pandemic; however, patents and other intellectual property claims directed at…

www.citizen.org

View attachment 742347


View attachment 742348
View attachment 742349

The above is the patent landscape for the BNT162 vaccine not mRNA.

 

[denel]

The IP belongs to University of Pennsylvania, so its American.

Patent Sublicense Agreement ​

This Patent Sublicense Agreement (“Agreement”) is between CELLSCRIPT, LLC, a Wisconsin limited liability company having a place of business at 726 Post Road, Madison, WI 53713, USA (“Cellscript”) and ModernaTx, Inc., a Delaware corporation having a place of business at 320 Bent Street, Cambridge, MA 02141, USA (“Company”). This Agreement is effective as of June 26, 2017 (the “Effective Date”). Each of Company and Cellscript are referred to herein as a “Party” and collectively as the “Parties”.

BACKGROUND

WHEREAS, mRNA RiboTherapeutics, Inc. (“mRNA RiboTherapeutics”) has an exclusive license from the Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”) for certain intellectual property comprising patents, patent applications and technology relating to use of modified ribonucleic acid (RNA) technology which was developed by Drs. Drew Weissman and Katalin Kariko of Penn’s Perelman School of Medicine as described in [***], and certain other intellectual property comprising patents, patent applications and technology relating to the modified RNA technology, inter alia, for reprogramming of mammalian cells to induced pluripotent stem cells, as described in [***], pursuant to the Second Amended and Restated Patent License Agreement which became effective as of December 20, 2016 (the “Penn License Agreement”), under which Cellscript has a sublicense from mRNA RiboTherapeutics in certain fields of use pursuant to the Amended and Restated Patent Sublicense Agreement which became effective as of December 20, 2016 (the “Cellscript Sublicense Agreement”), under which Cellscript has the right to further sublicense all or any part of the rights granted to Cellscript to other parties; and

EX-10.8

www.sec.gov

Of course, they will also never admit that CanSino was given a licence for part of the work.

 

[vi-va]

The above is the patent landscape for the BNT162 vaccine not mRNA.

Read again. I am not native speaker of English, you are. But I think if I understand right, BNT162 is the current vaccine Pfizer are making and selling in US.

Read the content again, dude.

 

[dbc]

Read again. I am not native speaker of English, you are. But I think if I understand right, BNT162 is the current vaccine Pfizer are making and selling in US.

Read the content again, dude.

Look up the legal definition of assignee before you make idiotic claims.

Assignee

A person to whom a property right is transferred by the person holding such rights under contract (the “assignor”). The act of transferring is referred to as “assigning” or “assignment” and is a concept used in contract and property law.

Definition of Assignment of IP - Cooley GO

Assignment of IP refers to the process by which ownership of work product created for a company by an employee or consultant is transferred to the entity.

www.cooleygo.com

Mainz, Germany, November 5, 2018 – BioNTech AG, a rapidly growing biotechnology company focused on the development of immunotherapies for the precise and individualized treatment of cancer and prevention of infectious diseases and the University of Pennsylvania (Penn), Philadelphia, USA, today announced that they have entered into a strategic research collaboration. The goal of the exclusive, multi-year partnership is to develop novel nucleoside-modified mRNA vaccine candidates for the prevention and treatment of various infectious diseases.
Under the terms of the agreement, BioNTech and the lab of Drew Weissman, MD, PhD, at Penn will exchange their in-depth knowledge and experience in mRNA research and development to advance the discovery of novel vaccine candidates. Penn will be responsible for a dedicated preclinical research program from discovery through to the completion of IND-enabling studies in up to ten infectious disease indications. BioNTech will be eligible to receive an exclusive worldwide license to further develop and commercialize product candidates arising from the research collaboration. If proprietary Penn technology is part of a new mRNA-based vaccine, the university will be eligible to receive additional milestone payments and royalties from BioNTech. Detailed financial terms were not disclosed.

https://biontech.de/sites/default/files/2019-08/20181104_20181105_BioNTech-and-the-University-of-Pennsylvania.pdf

Of course, they will also never admit that CanSino was given a licence for part of the work.

Not any different from claiming a smart phone with an American Operating System an American Chip is Chinese. see post #2

 

[vi-va]

Look up the legal definition of assignee before you make idiotic claims.

Assignee

A person to whom a property right is transferred by the person holding such rights under contract (the “assignor”). The act of transferring is referred to as “assigning” or “assignment” and is a concept used in contract and property law.

Definition of Assignment of IP - Cooley GO

Assignment of IP refers to the process by which ownership of work product created for a company by an employee or consultant is transferred to the entity.

www.cooleygo.com

Mainz, Germany, November 5, 2018 – BioNTech AG, a rapidly growing biotechnology company focused on the development of immunotherapies for the precise and individualized treatment of cancer and prevention of infectious diseases and the University of Pennsylvania (Penn), Philadelphia, USA, today announced that they have entered into a strategic research collaboration. The goal of the exclusive, multi-year partnership is to develop novel nucleoside-modified mRNA vaccine candidates for the prevention and treatment of various infectious diseases.
Under the terms of the agreement, BioNTech and the lab of Drew Weissman, MD, PhD, at Penn will exchange their in-depth knowledge and experience in mRNA research and development to advance the discovery of novel vaccine candidates. Penn will be responsible for a dedicated preclinical research program from discovery through to the completion of IND-enabling studies in up to ten infectious disease indications. BioNTech will be eligible to receive an exclusive worldwide license to further develop and commercialize product candidates arising from the research collaboration. If proprietary Penn technology is part of a new mRNA-based vaccine, the university will be eligible to receive additional milestone payments and royalties from BioNTech. Detailed financial terms were not disclosed.

https://biontech.de/sites/default/files/2019-08/20181104_20181105_BioNTech-and-the-University-of-Pennsylvania.pdf

Not any different from claiming a smart phone with an American Operating System an American Chip is Chinese. see post #2

Thanks. I am not sure I can understand those commercial and legal documents.
I trust you guys can understand, so you believe lab of Drew Weissman, MD, PhD, at Penn are holding those patents?

 

[Oruc]

Isnt the same BioNTech in cotract for chinese mRNA vaccine?

 

[dbc]

Thanks. I am not sure I can understand those commercial and legal documents.
I trust you guys can understand, so you believe lab of Drew Weissman, MD, PhD, at Penn are holding those patents?

for mRNA yes for BNT162 its a mix of IP owned by several institutions including the Government of US.

 

[vi-va]

for mRNA yes for BNT162 its a mix of IP owned by several institutions including the Government of US.

Thanks and Appreciate your help for me to understand this whole thing.

 

[denel]

Of course, they will also never admit that CanSino was given a licence for part of the work.

@Dariush the Great - will you stop trolling me. I have reported you already. please stop your childish behaviour.